Insider Trading & Ownership of ARCH Venture Partners XII, LLC

Location: Chicago, IL
Summary: The estimated value of insider holdings of ARCH Venture Partners XII, LLC is at least $177,469,096 dollars as of 14 Nov 2025. ARCH Venture Partners XII, LLC is the 10%+ Owner of Prime Medicine, Inc. and owns shares of Prime Medicine, Inc. (PRME) stock worth about $73.88M. ARCH Venture Partners XII, LLC is the 10%+ Owner of Neumora Therapeutics, Inc. and owns shares of Neumora Therapeutics, Inc. (NMRA) stock worth about $66.38M. ARCH Venture Partners XII, LLC is the 10%+ Owner of Rapport Therapeutics, Inc. and owns shares of Rapport Therapeutics, Inc. (RAPP) stock worth about $37.21M.
Signature: ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
All Insider Reports: All Insider Reports

Notify me when ARCH Venture Partners XII, LLC files a new Insider Trading report.

Ownership of ARCH Venture Partners XII, LLC

Symbol	Company	Relationship	Holdings Value	Past Year Net Change	Change %	Report Period
PRME	Prime Medicine, Inc.	10%+ Owner	$73,876,172	+$9,999,990	+16%	01 Aug 2025
NMRA	Neumora Therapeutics, Inc.	10%+ Owner	$66,380,119	+$4,999,977	+8.1%	27 Oct 2025
RAPP	Rapport Therapeutics, Inc.	10%+ Owner	$37,212,805			10 Jun 2024
MTSR	Metsera, Inc.	Director, 10%+ Owner	$0			13 Nov 2025

Sym	Company	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.